TriangleHEALTH PROFESSIONAL · SOURCE READING
Carboplatin
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Late Effects of the Urinary System / Therapy-Related Factors Affecting the Kidney / Chemotherapy
Carboplatin is a cisplatin analogue and is less nephrotoxic than cisplatin.
In a prospective, longitudinal, single-center, cohort study of children monitored for more than 10 years after cisplatin or carboplatin therapy, older age at treatment was found to be the major risk factor for nephrotoxicity, especially for patients who received carboplatin, while cisplatin dose schedule and cumulative carboplatin dose were also important predictors of toxicity. Platinum nephrotoxicity did not change significantly over 10 years.[15]
Source links and citations
The DCCSS-LATER 2 kidney analysis, a nationwide cross-sectional cohort study, evaluated 1,024 survivors (aged 18 years or older at the time of the study) for long-term tubular dysfunction. In multivariable risk analysis, after a median follow-up of 25.5 years, carboplatin was associated with potassium loss at a cumulative dose higher than 2,800 mg/m2 (OR, 5.1).[6]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice